These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36847048)

  • 1. BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: a case report and review of the literature.
    Ricco G; Seminerio R; Andrini E; Malvi D; Gruppioni E; Altimari A; Zagnoni S; Campana D; Lamberti G
    Anticancer Drugs; 2023 Nov; 34(10):1076-1084. PubMed ID: 36847048
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Sakamoto T; Arai K; Makishima K; Yamasaki A
    BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34969785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting
    Burkart J; Owen D; Shah MH; Abdel-Misih SRZ; Roychowdhury S; Wesolowski R; Haraldsdottir S; Reeser JW; Samorodnitsky E; Smith A; Konda B
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1035-1040. PubMed ID: 30181415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
    Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
    Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer].
    Zhang H; Gao J; Guo W; Yu B; Yang H; Liu Y
    Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):86-91. PubMed ID: 35224961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
    Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.
    Shimizu Y; Maruyama K; Suzuki M; Kawachi H; Low SK; Oh-Hara T; Takeuchi K; Fujita N; Nagayama S; Katayama R
    Cancer Lett; 2022 Sep; 543():215799. PubMed ID: 35724767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
    J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma.
    Nakano M; Shimada Y; Matsumoto Y; Saiki T; Zhou Q; Sasaki K; Moriyama M; Yoshihara K; Natsumeda M; Kuriyama Y; Takii Y; Watanabe G; Umezu H; Okuda S; Ikeuchi T; Wakai T; Saijo Y
    Clin J Gastroenterol; 2022 Apr; 15(2):413-418. PubMed ID: 35133626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
    Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J
    Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
    Joshi M; Rice SJ; Liu X; Miller B; Belani CP
    PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research Progress of Targeted Therapy for BRAF Mutation 
in Advanced Non-small Cell Lung Cancer].
    Liu X; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
    Wang Y; Chen Y; Yang Z; Qian F; Hu M; Lu J; Zhang Y; Zhang W; Wang K; Han B
    Ann Surg Oncol; 2022 Sep; 29(9):5666-5678. PubMed ID: 35543906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
    Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
    Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases.
    Karkouche R; Bachet JB; Sandrini J; Mitry E; Penna C; Côté JF; Blons H; Penault-Llorca F; Rougier P; Saint André JP; Emile JF
    Eur J Gastroenterol Hepatol; 2012 Dec; 24(12):1430-7. PubMed ID: 23114745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
    Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
    Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
    Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
    Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.